Ryzneuta Side Effects
Generic name: efbemalenograstim alfa
Note: This document contains side effect information about efbemalenograstim alfa. Some dosage forms listed on this page may not apply to the brand name Ryzneuta.
Applies to efbemalenograstim alfa: subcutaneous solution.
General
The most common adverse reactions with a frequency of 10% or greater were nausea, anemia, thrombocytopenia, fatigue, and bone pain.[Ref]
Cardiovascular
Frequency not reported: Capillary leak syndrome, aortitis
Hematologic
Very common (10% or more): Anemia (up to 12%), thrombocytopenia (up to 10%)
Frequency not reported: Sickle cell crisis, leukocytosis
Hypersensitivity
Frequency not reported: Serious allergic reactions
Oncologic
Frequency not reported: Myelodysplastic syndrome, acute myeloid leukemia
Other
Frequency not reported: Splenic rupture
Respiratory
Frequency not reported: Acute respiratory distress syndrome
Genitourinary
Very common (10% or more): Nausea (up to 42%)
Renal
Frequency not reported: Glomerulonephritis
More about Ryzneuta (efbemalenograstim alfa)
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: colony stimulating factors
Patient resources
Professional resources
Related treatment guides
References
1. Product Information. Ryzneuta (efbemalenograstim alfa). Evive Biotech. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
